Skip to main content
Clinical Trials/JPRN-UMIN000003783
JPRN-UMIN000003783
Completed
Phase 2

A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis. - Randomized phase II/III trial of preoperative versus postoperative chemotherapy in patients with resectable colorectal liver metastasis. (HiSCO-01)

Hiroshima Surgical study group of Clinical Oncology0 sites81 target enrollmentJuly 1, 2010

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Resectable liver metastasis from colorectal cancer
Sponsor
Hiroshima Surgical study group of Clinical Oncology
Enrollment
81
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2010
End Date
March 31, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hiroshima Surgical study group of Clinical Oncology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Multiple cancer patients 2\) Pregnant or lactating woman 3\) Steroid administration 4\) Patients must use flucytosine, phenytoin or warfarin potassium 5\) Uncontrollable hypertension or diabetes mellitus 6\) Diarrhea or peripheral neuropathy greater than grade 1 7\) Portal vein embolization 8\) Clinically significant pulmonary disease, coagulopathy or thrombosis. 9\) Clinically significant gastrointestinal bleeding, obstruction or ulcer. 10\) Clinically significant abdominal, pleural or pericardial effusion. 11\) Presence of psychological or central nervous system disorder. 12\) Major abdominal or thoracic surgery within 4 weeks. 13\) Presence of non\-healing bone fracture 14\) Hepatitis B virus infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancerChemo-naive hormone refractory prostate cancer
EUCTR2005-005249-21-GBBoehringer Ingelheim Ltd.105
Active, not recruiting
Not Applicable
A multicenter phase II trial of Recipient pre-treatment with Short-Term Rapamycin for the prevention of acute GVHD after hematopoietic stem cell transplantation in Elderly Patients - NDGraft Versus Host DiseaseMedDRA version: 9.1Level: LLTClassification code 10048396Term: Bone marrow transplant rejectionMedDRA version: 9.1Level: LLTClassification code 10000802Term: Acute GVH disease
EUCTR2008-002310-22-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Completed
Not Applicable
A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal Cancer(UMIN9510) -Additional study: How to predict the chemotherapy responseVery Low Rectal Cancer
JPRN-UMIN000030226ational Defense Medical College200
Completed
Phase 2
A Phase II/III Randomized multicenter Trial of Intersphincteric resection (ISR) with or without Preoperative Chemotherapy for very low-lying Rectal CancerVery Low Rectal Cancer
JPRN-UMIN000009510ational Cancer Center Hospital East200
Active, not recruiting
Phase 2
eo-adjuvant chemotherapy for Intersphincteric resection (ISR) in Low Rectal CancersRectal Cancerrectal cancer
JPRN-jRCTs031180278Ito Masaaki128